Stock Updates

A look at a High Market Cap Stock: Teva Pharmaceutical Industries Limited, TEVA

Teva Pharmaceutical Industries Limited, TEVA is in the exchange NYSE and its industry is Drug Manufacturers – Other in the sector of Healthcare. Based in Israel, Teva Pharmaceutical Industries Limited, TEVA  has a market cap of 38210.58. Since its IPO date on the 3/26/1990, Teva Pharmaceutical Industries Limited, TEVA performance year to date is -41.21%. Today Teva Pharmaceutical Industries Limited, TEVA has gained 0.48%, with a current price of 38.04.

Ownership of the company is 2.70% for insider ownership while institutional ownership is 57.10%. The management of the company have seen the company have a payout ratio of 77.90%. Return of assets are at 2.40%, with return on investment at 5.70%.

In terms of debt levels and profit levels, Teva Pharmaceutical Industries Limited, TEVA is seeing a long-term debt/equity of 1.05. While Total debt/equity is 1.17. With a profit margin of 7.80%, this is combined with a gross margin of 55.80%, and operating margin of 15.90%. Teva Pharmaceutical Industries Limited ability to meet debt levels, with a current ratio of 0.9, while the quick ratio is 0.6.

For the last year Teva Pharmaceutical Industries Limited, TEVA has seen a EPS growth of -48.90%. A performance for the year of -38.68%. The 52-week high is -41.74%, and the 52-week low is 2.48%. The average volume for Teva Pharmaceutical Industries Limited, TEVA is 853710.

With a target price of 54.87, can Teva Pharmaceutical Industries Limited, TEVA reach this target? Looking at the value indicators of Teva Pharmaceutical Industries Limited, TEVA. Teva Pharmaceutical Industries Limited has a P/E of 21.87 and a forward P/E of 6.87. Perhaps the more useful indicator than P/E, is PEG which has a value of 6.46. Teva Pharmaceutical Industries Limited also has a P/S and a P/B of 1.88 and 1.18 respectively. For P/cash, Teva Pharmaceutical Industries Limited has a value of 24.4, while it is *TBA for P/free cash flow.

At the current price of 38.04, Teva Pharmaceutical Industries Limited has a dividend yield of 3.59%. We see a return on equity of 5.70%.

Looking more long-term Teva Pharmaceutical Industries Limited, is projected to get an EPS growth for the next five years of 3.39%. In the short-term an EPS growth of 7.43% in the next year is forecasted. This is after a EPS growth of -48.90% for this year and for the last five years a -13.10% growth has been seen.

Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.

About the author

Peter Clarke

Leave a Comment